Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biology of metastatic renal cell carcinoma.
Milella M, Felici A. Milella M, et al. J Cancer. 2011;2:369-73. doi: 10.7150/jca.2.369. Epub 2011 Jun 24. J Cancer. 2011. PMID: 21850209 Free PMC article.
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Iacovelli R, Cartenì G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Cerbone L, Procopio G. Iacovelli R, et al. Among authors: milella m. Eur J Cancer. 2013 Jun;49(9):2134-42. doi: 10.1016/j.ejca.2013.02.032. Epub 2013 Mar 18. Eur J Cancer. 2013. PMID: 23518211
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
Iacovelli R, Farcomeni A, Sternberg CN, Cartenì G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Maria Ruggeri E, Berruti A, Procopio G. Iacovelli R, et al. Among authors: milella m. J Urol. 2015 Jun;193(6):1905-10. doi: 10.1016/j.juro.2014.11.092. Epub 2014 Nov 26. J Urol. 2015. PMID: 25433306
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?
Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, Conti A, Lugini A, Milella M, Galli L, Ortega C, Guida FM, Silletta M, Schinzari G, Verzoni E, Modica D, Crucitti P, Rauco A, Felici A, Ballatore V, Cascinu S, Tonini G, Carteni G, Russo A, Santini D. Pantano F, et al. Among authors: milella m. PLoS One. 2015 Apr 17;10(4):e0120427. doi: 10.1371/journal.pone.0120427. eCollection 2015. PLoS One. 2015. PMID: 25885920 Free PMC article.
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E. Procopio G, et al. Among authors: milella m. Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19. Clin Genitourin Cancer. 2018. PMID: 29753637
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis.
Rossi A, Noia VD, Gkountakos A, D'Argento E, Sartori G, Vita E, Monteverdi S, Lombardo F, Iacovelli R, Carbognin L, Sperduti I, Milella M, Tortora G, Bria E, Pilotto S. Rossi A, et al. Among authors: milella m. Immunotherapy. 2019 Jul;11(10):921-930. doi: 10.2217/imt-2018-0198. Epub 2019 Jun 3. Immunotherapy. 2019. PMID: 31155995
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Santoni M, et al. Among authors: milella m. Cancers (Basel). 2019 Dec 30;12(1):84. doi: 10.3390/cancers12010084. Cancers (Basel). 2019. PMID: 31905816 Free PMC article.
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Iacovelli R, et al. Among authors: milella m. Target Oncol. 2020 Aug;15(4):495-501. doi: 10.1007/s11523-020-00732-y. Target Oncol. 2020. PMID: 32671807
665 results